Diagnostic Green’s Post

Lenvatinib and pembrolizumab added to transarterial chemoembolisation (TACE) significantly improves PFS and shows an early trend toward improved OS versus TACE alone, according to a first interim analysis of the phase III LEAP-012 trial of intermediate-stage #HCC presented at #ESMO24. TACE is the standard-of-care therapy in this setting but is not curative, so there is an unmet need for improved locoregional treatments. Lorenza Rimassa believes the positive PFS data could influence future #ClinicalPractice, although longer follow-up is needed. 👇Read the full commentary on the #ESMODailyReporter https://ow.ly/loxX50TnAL5

Another particularly interesting session at ECTRIMS 2024 was focussed on neuroprotection. One point that particularly resonated with our research was the discussion of a therapeutic lag in repair trials - eloquently raised by Bruno Stankoff. Given the benefit of remyelination is the prevention or delay of disability accumulation (through insulating and protecting damaged nerve fibres), this could take years to be fully apparent. This is why we are so focussed on sensitive outcome measures for our trials and why we need to conduct long term follow up studies to our phase 2 trials to see the long term effects of remyelinating drugs. This is going to be such an important point when it comes to licensing a remyelination promoting treatment. #ECTRIMS2024 #multiplesclerosis #remyelination #clinicaltrials

Interesting. Key could be the ability to screen and identify the fibrosis /activity /steatosis of patients in the PCP and ENDO setting so that the patients that are sent have a good reason to be referred. Currently a vast majority of patients sent to specialists by generalists turn out to be F0/F1 with TE/VCTE. That is great for the patient but a diagnostic "failure". Screen more patients and identifying those that have F>2/A>2 = sending a smaller number of patients to a specialist who have a much higher likelihood of needing to be with a specialist

¹⁸F-FAPI PET/CT parameters after treatment and their changes from baseline can predict the pathologic response to nCC in LA-ESCC participants. https://ow.ly/uc6050Txxeb #MolecularImaging #EsophagealCancer #MedicalImaging

Overall survival rate improved with the addition of pembrolizumab. #lungcancermatters     #accesstotreatmentisaccesstolife    http://prac.co/l/2yp25qxp

Psoriasis Headline News from #EADV2024 Results from the Phase 2 OLE Study of ESK-001, an oral TYK2 inhibitor for the treatment of psoriasis, presented at the Late Breaking session, showed  dose-dependent sustained increases in PASI endpoint responses observed over time, with the majority of patients (93% as observed, 82.7% using modified non-responder imputation) achieving PASI 75, the primary endpoint, at the highest dose of 40 mg twice daily. ESK-001 continued to show a favorable safety profile in the OLE. ESK-001 is an oral TYK2 inhibitor currently being evaluated in the Phase 3 ONWARD clinical program for the treatment of psoriasis. #EADV2024 #LateBreaking #ESK001

I've been learning more about #Dojolvi, which is a special oil in #pharma for Genetic Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD). These can be recessive metabolic disorders from #birth. Only one linked DNA strand is required (meaning inheriting it from one parent only). The disorders in this cluster are CACT, CPT I, CPT II, LCHAD, TFP & VLCAD. The body cannot digest certain acids. These are acids that are absolutely in the American Diet and in every restaurant. Some oils are better than others whether short or medium chain. Some diets are better than others. I.e. Intermittent Fasting and Paleo can help improve symptoms & #energy. DOJOLVI, #triheptanoin, was recently approved by the FDA. I spoke to a Dojolvi Pharmacy Rep this morning. I asked him what the cost was listed as before Prior Authorization. He said it depended on the dose prescribed. For the specific monthly dose, the contracted price is $97,000.00 and the Cash-Pay-Out Of Pocket cost is $55,000.00. Every Month. This could be viewed as a price of #freedom with energy sustenance. An individual with prior authorization for DOJOLVI at this dose, has a minimum personal equity of $1,164,000.00 (1.164M) annually to date of death; not including inflation or other rate adjustments. Are you including your health benefits, premiums, co-insurance, rx, in your #QuickBooks Equity registers? I also learned of several rare disorder grant programs, which help patients cover costs. When I think of those business models, I don't know enough about them - yet I can imagine the philanthropy behind them; in addition to the skill required for grant writing or acquiring donor funding. I also think about women who are under-served; and all the metabolism disorders in the world that haven't been diagnosed yet, or that could be #misdiagnosed. I personally feel like Genetic Disease Testing & checking your DNA for Cancer Risks is #priceless. Regardless of the initial cost, knowing your personal factors can help anyone start to live a life they've imagined; mitigate risks; or prepare for upcoming life changes. Cheers to #health.

Helsinn is committed to raising awareness of the importance of antiemetic guidelines. In synch with the #MASCC24 annual meeting, Helsinn reminds HCPs that MASCC/ESMO released new antiemetic guidelines. Key practice changing updates include recommended use of a triple combination of a NK1 receptor antagonist (RA), 5-HT3 RA and steroids prophylactically in situations where emetogenic potential is now considered at the high end of the moderate category (eg, for patients receiving carboplatin (AUC ≥ 5), for women <50 receiving oxaliplatin, for patients receiving ADCs such as trastuzumab-deruxtecan and sacituzumab-govitecan). #supportivecare #antiemetics #CINV

The VICTORION-INITIATE trial showed that in patients with #ASCVD on maximally tolerated statin therapy with inadequate lipid control, inclisiran was superior to usual care in achieving a clinically significant reduction in LDL-C. Get the trial details here: https://bit.ly/4aKD93m #ACC24

#Optometrists, need an updated game plan for managing your #maculardegeneration patients with the newly approved treatments for geographic atrophy, SYFOVRE® (pegcetacoplan injection) HCP and Iveric Bio, An Astellas Company's IZERVAY? Here is a really helpful article with practical guidance from a group of experts - Paul Karpecki, Mohammad Rafieetary , OD, FAAO, FORS, Dipl ABO, ABCMO, Carl Regillo, Elizabeth Yeu, MD, Diana Shechtman OD FAAO, etc. https://lnkd.in/g4KWQUfu #optometry #comprehensivecare #2020habits #optometrist #eyecare #amd